Japan to raid Novartis over alleged data fabrication: reports

Japanese authorities are preparing to raid the local arm of Swiss pharmaceutical giant Novartis over data fabrication claims, reports said Friday.

A health ministry panel of experts has concluded that Novartis Pharma KK should be held responsible for studies at various universities that used manipulated data on a popular , the Asahi Shimbun and other media said.

The studies suggested the drug—sold under the name Diovan in Japan and licensed for use in more than 100 countries—had some prophylactic effect on strokes and angina.

The firm used data from the studies to market its drug, playing up its supposed additional benefits.

"The panel is examining the possibility of exaggerated advertisement which is a violation of the Pharmaceutical Affairs Act and will urge the government to take strict actions," against Novartis Pharma KK, the Asahi said.

Upon receipt of the panel's interim report next week, "the plans to carry out an on-site investigation" into the company, the Asahi said.

The panel's report will also say the company and the universities must be held accountable for the faulty studies, regardless of the degree of their involvement, the Mainichi Shimbun said.

The panel will also urge the authorities to estimate the of the studies on the nation's finances, the Mainichi said.

Novartis has maintained that the company had no knowledge of episodes in which a now-former employee allegedly used bogus data in a string of Japanese university studies that exaggerated the drug's effectiveness in preventing strokes and .

The worker had hidden his affiliation with Novartis during the studies at various institutions that used incomplete clinical data to demonstrate the effects of the drug, hospitals and media reports have said.

The worker and other researchers involved in studies have denied to the panel that they manipulated the data, the Mainichi previously said.

Novartis Pharmaceuticals chief David Epstein was called to meet with Health Minister Norihisa Tamura and promised Thursday to cooperate with Tokyo's probe into the matter.

Epstein apologised for the concern the incident has caused, but did not admit the company's role in the data fixing allegations, a company spokeswoman said.

Tokyo's Jikei University School of Medicine has retracted research that appeared in respected medical journal The Lancet six years ago due to data fabrication.

Kyoto Prefectural University of Medicine also concluded that its studies on the drug used incomplete clinical data.

add to favorites email to friend print save as pdf

Related Stories

Novartis chief sees sales dip until mid-2013

Oct 07, 2012

Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Britain snubs costly Novartis blood cancer drug

Feb 13, 2013

British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Recommended for you

New system targets germs in donated blood plasma

8 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.